Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Zhongyu Yuan"'
Autor:
Anhua Li, Yanxia Shi, Xin An, Kuikui Jiang, Zhongyu Yuan, Ruhai Zou, Shusen Wang, Wenwen Wei, Ruoxi Hong, Wen Xia, Peng Sun, Wei Zheng, Xiaoju Diao, Cong Xue, Jia Jia Huang, Fei Xu, Riqing Huang
Publikováno v:
Breast Cancer Research and Treatment. 173:619-628
Ovarian function is important for optimizing endocrine treatment in patients with hormone receptor-positive (HR+) early breast cancer (eBC). The aim of the study was to determine whether patients’ pretreatment levels of anti-Mullerian hormone (AMH)
Autor:
Anthony Gonçalves, Gilles Houvenaeghel, Fei Xu, Zhongyu Yuan, Rongzhen Luo, Shusen Wang, Haifeng Li, Riqing Huang, Alexandre de Nonneville, Xin An, Xuefen Lei, JiBin Li, Yanxia Shi, Cong Xue
Publikováno v:
CancerReferences. 126
Background Current guidelines recommend adjuvant chemotherapy for patients with small, lymph node-negative, triple-negative breast cancer (TNBC) measuring >5 mm (T1b disease), but clinical evidence to support this recommendation is lacking. Thus, the
Autor:
Huiping Li, Yongmei Yin, Xiao Jia Wang, Zhongyu Yuan, Cuizhi Geng, Pin Zhang, Xichun Hu, Yongsheng Wang, Jing Cheng, Binghe Xu, Rou-Jun Peng, Zefei Jiang, Qingyuan Zhang, Jian Liu, Baochun Zhang, Zhongsheng Tong, Shude Cui, Shaohua Zhang, Hongming Pan, Hong Zheng, Li Tang, Tao Sun, Yuee Teng, Qiang Yao, Jian Huang, Min Yan, Jinsong Lu, Rongguo Qiu, Junlan Yang, Ping Sun
Publikováno v:
The Lancet Oncology. 18:371-383
Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2 trials. The aim of this phase 3 trial was to compare the efficacy and safety of utidelone plus capecitabine versus
Autor:
Qiufan Zheng, Tao Qin, Rongzhen Luo, Zhongyu Yuan, Wenqi Jiang, Shusen Wang, Yanhua Yang, Xin An, Yanxia Shi, Jia-Bin Lu, Fei Xu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background Topoisomerase II alpha (TOP2A) protein has been shown to be a proliferation marker associated with tumor grade and Ki67 index. The prognostic effect of TOP2A seems different among different subtypes of breast cancer. The current study eval
Autor:
Huijuan Qiu, Feifei Zhou, Chenxi Yin, Liangping Xia, Guifang Guo, Fang Wang, Xuxian Chen, Yuming Rong, Zhongyu Yuan, Xi Wang, Wenzhuo He
Publikováno v:
Clinical Breast Cancer. 12:404-411
Background The lymph node ratio (LNR) classification has shown superiority to pN staging (the number of positive lymph nodes) in breast cancers, but it has not been examined according to whether sufficient lymph nodes have been dissected. Methods All
Autor:
Xiaoyu Teng, Donggen Liu, Tao Qin, Yanxia Shi, Zhongyu Yuan, Cong Xue, Shusen Wang, Roujun Peng, Li Zhang, Xi Wang
Publikováno v:
Cancer Science
Breast cancer research and treatment by different subtypes is an inevitable trend. We investigated the clinicopathologic features and outcomes of different breast cancer subtypes in Southern China. A total of 5809 patients with invasive ductal carcin
Autor:
Zhongyu Yuan, Tao Qin, Shusen Wang, Xiaoyu Teng, Jiehua He, Donggen Liu, Roujun Peng, Yanxia Shi
Publikováno v:
Medical Oncology. 29:401-405
The aim of this study was to analyze the prognostic value of EGFR expression for patients with triple-negative breast cancer (TNBC). Clinical data of these patients were collected and analyzed, and immunohistochemical staining for EGFR was performed
Publikováno v:
Chinese Journal of Cancer. 29:413-419
The brain is one of the most common metastatic sites of breast cancer. Brain metastases develop in 10%-15% of patients with breast cancer and are associated with poor prognosis. The purpose of this retrospective study was to analyze the clinical char
Publikováno v:
Medical Oncology. 30
The aim of this study was to evaluate the prognostic value of light chain 3 (LC3) expression in triple-negative breast cancer (TNBC) and describe the association of LC3 expression with the occurrence of metastasis. LC3 expression in tissue microarray
Autor:
Tao Qin, Roujun Peng, Xiaoyu Teng, Jie-Wen Peng, Donggen Liu, Yanxia Shi, Xi Wang, Xiaomei Jiang, Gui-Nan Lin, Zhongyu Yuan, Shusen Wang
Publikováno v:
Medical oncology (Northwood, London, England). 29(2)
Patients suffering from triple-negative breast cancer (TNBC) have poor prognosis mainly because no standard treatment is currently available. Our objectives were to explore the prognostic factors for first relapse of patients with TNBC. A cohort of 6